Key result
Chronic elevation of Endothelin-1 alone did not impair endothelium-dependent relaxation or reduce eNOS activity across mouse models, cultured cells, and human resistance arteries (P>0.05).
Why the study?
Increased ET-1 is associated with reduced NO bioavailability and impaired vascular function, but whether chronic elevation of ET-1 directly impairs endothelium-dependent relaxation remains elusive.
Does chronic elevation of Endothelin-1 directly impair endothelium-dependent relaxation in vascular models and human subjects?
Does chronic elevation of Endothelin-1 directly impair endothelium-dependent relaxation in vascular models and human subjects?
p-value: p=>0.05
Chronic elevation of Endothelin-1 alone does not directly impair endothelium-dependent relaxation, challenging the assumption that hyperendothelinemia is the sole direct cause of endothelial dysfunction.
Challenges assumed direct ET-1 role in endothelial dysfunction; leaves open its contribution to hypertension and requires clinical validation.
Endothelin-1 (ET-1) is a powerful vasoconstrictor peptide considered to be causally implicated in hypertension and the development of cardiovascular disease. Increased ET-1 is commonly associated with reduced NO bioavailability and impaired vascular function; however, whether chronic elevation of ET-1 directly impairs endothelium-dependent relaxation (EDR) remains elusive. Herein, we report that (1) prolonged ET-1 exposure (ie, 48 hours) of naive mouse aortas or cultured endothelial cells did not impair EDR or reduce eNOS (endothelial NO synthase) activity, respectively ( P >0.05); (2) mice with endothelial cell–specific ET-1 overexpression did not exhibit impaired EDR or reduced eNOS activity ( P >0.05); (3) chronic (8 weeks) pharmacological blockade of ET-1 receptors in obese/hyperlipidemic mice did not improve aortic EDR or increase eNOS activity ( P >0.05); and (4) vascular and plasma ET-1 did not inversely correlate with EDR in resistance arteries isolated from human subjects with a wide range of ET-1 levels (r=0.0037 and r=−0.1258, respectively). Furthermore, we report that prolonged ET-1 exposure downregulated vascular UCP-1 (uncoupling protein-1; P <0.05), which may contribute to the preservation of EDR in conditions characterized by hyperendothelinemia. Collectively, our findings demonstrate that chronic elevation of ET-1 alone may not be sufficient to impair EDR.
No takes yet. Share an insight, caveat, or question.
Grunewald et al. (2019) studied this question. Chronic elevation of Endothelin-1 (ET-1) vs. Normal ET-1 levels or ET-1 receptor blockade was evaluated on Endothelium-dependent relaxation (EDR) and eNOS activity (p=>0.05). Chronic elevation of Endothelin-1 alone did not impair endothelium-dependent relaxation or reduce eNOS activity across mouse models, cultured cells, and human resistance arteries (P>0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: